OFFICAL PROJECT SITE
Novel Target for Treatment of Chronic Inflammatory Diseases — Notid
Lipum attends the largest Nordic Partnering Conference
- This is the right arena for Lipum, says Einar Pontén. It gives us an opportunity to meet people and inform about our progress and long-term plan. Lipum will participate September 10-12th at Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry. The NLSDays [...]
BioStock’s article series on autoimmune disease: Drug development for RA and MS
Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be severe. There is a strong need for new therapies and therefore there is a large market potential, especially for treatments targeting rheumatoid arthritis and multiple sclerosis. In this third segment [...]
Lipum presents at Biostock Live
On August 27, Lipums CEO Einar Pontén will present our recent progress towards a novel treatment of chronic inflammatory diseases. The presentation will be broadcasted live on the web from 10am. On this autumn's first BioStock Live Investor Event you have the chance to listen to presentations and talk with [...]
Lipum invites to shareholders meeting
On August 28, Lipum shareholders will meet at Clarion Hotel Arlanda Airport. The recent progress and plans for the future will be presented and discussed. More detailed information will be sent out in personal mail. Warm welcome!
Kallelse till årsstämma i Lipum AB
Aktieägarna i Lipum AB, org. nr. 556813-5999 (“Lipum”), kallas härmed till årsstämma fredagen den 28 juni 2019, kl. 09:00 på Tvistevägen 48C i Umeå. […]
Getting roasted by investors
As a Horizon 2020 beneficiary we are invited to the SME Instrument Phase 2 Welcome Day organized by the European Innovation Council (EIC) Pilot in Brussels, May 22-23. Besides business networking the agenda includes: “Get roasted by investors – ready to go?”, “Success story from SME Instrument Innovator” and “Learn [...]
Program:
European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741
Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases
Project budget:
3.2 M€
Funding from the EU:
2.2 M€
Start:
2018-11-01
End:
2020-11-30